

# Hepatitis, Unspecified

## (including Hepatitis D and E)

### 1. DISEASE REPORTING

#### A. Purpose of Reporting and Surveillance

1. To better characterize the epidemiology of infectious hepatitis not due to hepatitis A, B, or C viruses.
2. To recommend appropriate preventive measures, including immunization against other types of hepatitis which are vaccine-preventable.

#### B. Legal Reporting Requirements

1. Health care providers: notifiable to local health jurisdiction within 3 work days
2. Hospitals: notifiable to local health jurisdiction within 3 work days
3. Laboratories: no requirements for reporting
4. Local health jurisdictions: notifiable to Washington State Department of Health (DOH) Communicable Disease Epidemiology Section (CDES) within 7 days of case investigation completion or summary information required within 21 days

#### C. Local Health Jurisdiction Investigation Responsibilities

1. Begin investigation within one working day.
2. Facilitate transport of specimens to PHL for confirmatory testing.
3. Initiate appropriate infection control measures.
4. Hepatitis D virus and hepatitis E virus infections should be reported to DOH as unspecified infectious hepatitis. Report all *confirmed* cases to CDES. Complete the hepatitis, unspecified report form (<http://www.doh.wa.gov/notify/forms/hepu.pdf>) and enter the data in the Public Health Issues Management System (PHIMS).

### 2A. HEPATITIS D AND ITS EPIDEMIOLOGY

#### Background

Hepatitis D infections occur worldwide, but the prevalence varies widely. An estimated 10 million people are infected with hepatitis D virus and its helper virus hepatitis B. Hepatitis D infection occurs epidemically or endemically in populations at high risk of hepatitis B virus infection, such as populations in which hepatitis B is endemic (highest in parts of Russia, Romania, southern Italy, Africa and South America); in hemophiliacs, drug addicts and others who come in frequent contact with blood; in institutions for the developmentally disabled; and, to a lesser extent, in male homosexuals.

**A. Etiologic Agent**

Hepatitis D virus is a virus-like particle consisting of a coat of HBsAg and a unique internal hepatitis D antigen. Encapsulated with the antigen is the genome, a single-stranded RNA. Hepatitis D virus is unable to infect a cell by itself and requires coinfection with hepatitis B virus to undergo a complete replication cycle. Synthesis of hepatitis D virus, in turn, results in temporary suppression of synthesis of hepatitis B virus components.

**B. Description of Illness**

Onset is usually abrupt, with signs and symptoms resembling those of infections with hepatitis B virus; illness may be severe. Hepatitis D virus infection is always associated with a coexistent hepatitis B virus infection, either simultaneous new infections (co-infection) or a chronic hepatitis B infection (superinfection). Hepatitis D may be self-limiting or it may progress to chronic hepatitis. Children may have a particularly severe clinical course with usual progression to chronic active hepatitis. With superinfection, hepatitis D infection can be misdiagnosed as an exacerbation of chronic hepatitis B.

**C. Hepatitis D in Washington State**

An outbreak of hepatitis B among injecting drug users in Pierce County in April 2000 included 60 cases and resulted in three deaths among cases co-infected with hepatitis D virus.

**D. Reservoirs**

Humans.

**E. Modes of Transmission**

Transmission is thought to be similar to that of hepatitis B virus – by exposure to infected blood and serous body fluids, contaminated needles, syringes and plasma derivatives such as antihemophilic factor, and through sexual transmission. All people susceptible to hepatitis B virus infection or who have chronic hepatitis B infection can be infected with hepatitis D virus.

**F. Incubation Period**

Approximately 2–8 weeks.

**G. Period of Communicability**

Blood is potentially infectious during all phases of active hepatitis D infection. Peak infectivity probably occurs just prior to onset of acute illness, when particles containing the hepatitis D antigen are readily detected in the blood. Following onset of symptoms, viremia probably falls rapidly to low or undetectable levels but experimental evidence suggests infectivity may persist.

**H. Treatment**

Treatment is supportive for acute infection. For chronic hepatitis B and D virus infection, antiviral treatment or liver transplantation may be considered.

**2B. HEPATITIS E AND ITS EPIDEMIOLOGY****Background**

Hepatitis E virus is the major etiologic agent of enterically transmitted non-A, non-B hepatitis throughout the world. Outbreaks and sporadic cases of hepatitis E occur over a wide geographic area, primarily in countries with inadequate environmental sanitation. Outbreaks are often waterborne, but sporadic cases and epidemics not clearly related to water have been reported. The highest rates of clinically evident disease have been in young to middle aged adults; lower disease rates in younger age groups may be the result of anicteric and/or subclinical hepatitis E virus infection. In the United States and most other industrialized countries, almost all hepatitis E cases are among travelers returning from hepatitis E virus endemic areas.

**A. Etiologic Agent**

The hepatitis E virus (HEV) is a single-stranded RNA virus.

**B. Description of Illness**

The clinical course is similar to that of hepatitis A. Infection may be anicteric. The case-fatality rate is similar to that of hepatitis A except in pregnant women, where the rate may reach 20% among those infected during the third trimester of pregnancy. A recent report described chronic hepatitis E in a small number of organ-transplant recipients in Europe (NEJM 2008;358(8):814) but chronic infections are very rare.

**C. Hepatitis E in Washington State**

There have been two cases reported in the past five years, both associated with travel to India.

**D. Reservoirs**

Humans along with wild and domestic animals, particularly swine.

**E. Modes of Transmission**

Hepatitis E virus is transmitted primarily by the fecal-oral route; fecally contaminated drinking water is the most commonly documented vehicle of transmission. Fecal-oral transmission probably can occur from person to person, though secondary household cases are not common during outbreaks. Recent studies have suggested that hepatitis E may in fact be a zoonotic infection with coincident areas of high human infection.

**F. Incubation Period**

The range is 15 to 64 days; the mean incubation period has varied from 26 to 42 days in different epidemics.

**G. Period of Communicability**

Not known. However, hepatitis E virus has been detected in stools 14 days after the onset of jaundice and approximately 4 weeks after ingestion of contaminated food or water and persists for about 2 weeks.

**H. Treatment**

Treatment is supportive.

### 3. CASE DEFINITIONS

#### A. Clinical Description

An illness with a) discrete onset of symptoms and, b) jaundice or elevated serum aminotransferase levels.

#### B. Laboratory Criteria for Diagnosis

##### Hepatitis D

- Serum aminotransferase levels > 2.5 times the upper limit of normal, and
- Immunoglobulin M (IgM) anti-HAV negative, and
- Anti-HCV negative, and
- HBsAg or IgM anti-HBc positive, and
- Positive result from a research laboratory for hepatitis D RNA or detection of antibody to hepatitis D virus.

##### Hepatitis E

- Serum aminotransferase levels > 2.5 times the upper limit of normal, and
- Immunoglobulin M (IgM) anti-HAV negative, and
- IgM anti-HBc negative (if done) or HbsAg negative, and
- Anti-HCV negative, and
- Positive result from a research laboratory for hepatitis E RNA or detection of antibody to hepatitis E antigen.

#### C. Case Definition (DOH)

Confirmed: A case that meets the clinical case definition and is laboratory confirmed.

### 4. DIAGNOSIS AND LABORATORY SERVICES

#### A. Diagnosis

Diagnosis of hepatitis D is made by detection of total antibody to hepatitis D virus (anti-HDV) by EIA. A positive IgM titer indicates ongoing replication; reverse transcription PCR is the most sensitive assay for detecting hepatitis D viremia.

Diagnosis of hepatitis E depends on clinical and epidemiologic features and exclusion of other etiologies of hepatitis, especially hepatitis A, by serologic means. Several diagnostic tests are available including enzyme immunoassays and Western blot assays to detect IgM and IgG anti-HEV in serum; polymerase chain reaction tests to detect hepatitis E virus RNA in serum and stool, and immunofluorescent antibody blocking assays to detect antibody to hepatitis E antigen in serum and liver.

**B. Tests Available at the Washington State Department of Health Public Health Laboratories (PHL)**

PHL does not perform testing for hepatitis D or E but will forward specimens to the CDC for testing or confirmation. Please contact Communicable Disease Epidemiology Section for approval prior to submitting specimens.

**C. Specimen Collection**

Serum should be refrigerated and transported cold. Specimens should be submitted with a completed DOH PHL Virus Examinations form available at:

<http://www.doh.wa.gov/EHSPHL/PHL/Forms/SerVirHIV.pdf>

**5. ROUTINE CASE INVESTIGATION**

Interview the case or others who may be able to provide pertinent information.

**A. Evaluate the Diagnosis**

Confirm that the case's illness is consistent with acute viral hepatitis. Diagnosis is supported by presence of risk factors such as intravenous drug use for hepatitis D or international travel for hepatitis E. Facilitate transport of positive specimens to Public Health Laboratories for confirmatory testing.

**B. Identify Potential Sources of Infection**

Ask the case about potential exposures 2–8 weeks before onset of illness, including any persons (e.g., household member, sex partners, shared injection equipment, shared a meal, others in a travel group) who had a compatible illness. Obtain each person's name and contact information. Newly identified cases should be reported and investigated in the same manner as the index case.

**C. Identify Close Contacts or Others Potentially Exposed to the Patient**

1. For hepatitis D identify persons potentially exposed to the case during the communicable period. These include household members, sexual contacts, and needle sharing contacts and others potentially exposed to blood or sexual fluids. Evaluate for symptoms and educate about preventing transmission. Recommend hepatitis B vaccination to contacts susceptible to hepatitis B.
2. If the case has donated blood or plasma in the 8 weeks before onset, see Section 7C.
3. If the patient is pregnant, see Section 7D.

**D. Environmental Evaluation**

None, unless a commercial food service facility, child care center, or public water supply appears to be implicated as the source of infection.

**6. CONTROLLING FURTHER SPREAD****A. Infection Control Recommendations / Case Management**

1. Hepatitis D: Hospitalized patients should be cared for using standard precautions.

2. Hepatitis E: Hospitalized patients should be cared for using standard precautions. In addition, contact precautions should be used for diapered or incontinent individuals for the duration of symptoms.
3. Patients susceptible to hepatitis A should be vaccinated against hepatitis A.

**B. Contact Management****1. Symptomatic Contacts**

Symptomatic close contacts of a confirmed case should be referred to a healthcare provider and tested.

**2. Postexposure Prophylaxis**

No products are available to prevent hepatitis D or E in contacts.

**3. Education**

All persons exposed to the case or the same source as the case should be educated about signs and symptoms of hepatitis in both children and adults, and methods to prevent transmission. They should be informed that persons may be infectious without being ill. For hepatitis D, recommend hepatitis B vaccination to contacts susceptible to hepatitis B.

**7. MANAGING SPECIAL SITUATIONS****A. Case is a Health Care Worker with Hepatitis D**

If the case is a dentist, physician, nurse, or other health care worker with potential for exposing patients by blood or other body fluids:

1. The person should be discouraged from working until the acute clinical illness has resolved;
2. Upon return to work, special precautions should be practiced until the worker is no longer infectious, including:
  - a. wearing gloves for all procedures during which the hands will be in contact with the patients' mucosal surfaces or broken skin;
  - b. avoiding situations involving sharps that could lead to exposures of susceptibles to blood or objects contaminated with blood of the case;
  - c. careful and frequent hand washing.
3. Chronically infected health care workers should be encouraged to voluntarily seek confidential counseling from employee health services regarding risk reduction strategies, which evaluation would include a review of their practice by an expert panel.

**B. Outbreak of Hepatitis D**

When two or more cases occur associated with a common exposure, conduct a search for additional cases. Institute strict aseptic techniques. If a plasma derivative such as antihemophilic factor, fibrinogen, pooled plasma or thrombin is implicated, notify the bloodbank to withdraw the lot from use and trace all recipients of the same lot in a search for additional cases. Provide education and outreach to intravenous drug users in the

community to reduce bloodborne transmission and make available hepatitis B vaccination for those susceptible to that infection.

**C. Case Is a Recent Blood Donor or Recipient**

The blood bank should be notified so that any unused product can be recalled.

**D. Case Is Pregnant**

Follow the perinatal hepatitis B recommendations if the pregnant woman is hepatitis B virus DNA or HBsAg-positive.

Hepatitis E virus infection can be severe in a pregnant woman. Consult with Communicable Disease Epidemiology Section.

**8. ROUTINE PREVENTION****A. Immunization Recommendations**

None.

**B. Prevention Recommendations****1. Hepatitis D**

For at-risk persons such as injection drug users, follow prevention recommendations for hepatitis B including vaccination for those susceptible to hepatitis B virus infection. Preventing hepatitis B virus infection prevents infection with hepatitis D virus. Among persons with chronic hepatitis B virus, the only effective measure is avoiding exposure to any potential source of hepatitis D. Immune globulin, hepatitis B immune globulin, and hepatitis B vaccine do not protect persons with chronic hepatitis B virus from infection by hepatitis D virus. Studies suggest that measures which decrease sexual exposure and needle sharing have been associated with a decline in the incidence of hepatitis D virus infection.

**2. Hepatitis E**

Routine precautions should be taken during travel in risk areas to assure safe food and water, particularly for women who may be pregnant.

**ACKNOWLEDGEMENTS**

This document is a revision of the Washington State Guidelines for Notifiable Condition Reporting and Surveillance published in 2002 which were originally based on the Control of Communicable Diseases Manual (CCDM), 17<sup>th</sup> Edition; James Chin, Ed. APHA 2000. We would like to acknowledge the Oregon Department of Human Services for developing the format and select content of this document.

**UPDATES**